Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
NEAL DAVID EPSTEIN · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2022 · $582,088 — Endosymbionts are unicellular organisms that reside inside the cells of a host organism and can have dramatic influence over the host, ranging from nutritional provisioning to immune function and in the case of filarial nematodes, their actual development. It is estimated that more than 75% of inse…
James Pickel · NATIONAL INSTITUTE OF MENTAL HEALTH · 2022 · $2,105,007 — 1) Production of rodent transgenics Mouse transgenic production projects: 22 Rat transgenic production projects: 4 Cryopreservation projects: 26 Rederivation projects: 20 2) SARS-Cov2 a) Fibroblast cultures have been propagated using methods developed in the lab (see below) over several years. Thes…
Margaret Juliana McElrath · FRED HUTCHINSON CANCER CENTER · 2022 · $4,637,125 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial entitled “A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the …
Rachel R. Caspi · NATIONAL EYE INSTITUTE · 2022 · $385,523 — GENERAL OVERVIEW: The Flow Cytometry Core at NEI provides flow cytometry analytical and sorting equipment and services to the NEI Intramural community. It utilizes and develops state-of-the-art sample preparation, data acquisition and analysis, and sorting procedures in collaborative research proje…
Eugene V Koonin · NATIONAL LIBRARY OF MEDICINE · 2022 · $415,318 — The rapid accumulation of genome sequences and protein structures during the last decade has been paralleled by major advances in sequence database search methods as well as protein structure prediction. The powerful Position-Specific Iterating BLAST (PSI-BLAST) method developed at the NCBI forms th…
Cheng Cheng · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $2,325,099 — During the past year, we have created and tested new vaccine candidates, including envelope proteins and fusion peptides displayed on carrier proteins. In addition, we have continued our work testing different methods and routes of administration as well as prime/boost combinations to further optimi…
William Copeland · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2022 · $461,744 — During this fiscal year we continued to devote major effort to work aimed at applications of molecular dynamics and quantum mechanics/molecular mechanics simulations required to help support the computational chemistry and molecular modeling needs of NIEHS scientists. Some projects involved creatio…
Peter D Kwong · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $1,269,871 — Based on our understanding of spike- or envelope-based mechanisms of humoral evasion, we are working to design envelope-based immunogens with these evading mechanisms disabled. Such modified immunogens with weakened defenses may elicit more broadly neutralizing antibodies. We have also devised prote…
Tongqing Zhou · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $712,375 — The recent emergence of SARS-CoV-2 Omicron and its sub-variant evaded neutralization by antibodies elicited against the viral spike protein of early variants. Rapid development of molecular probes based on new variants of concern and identification of neutralizing monoclonal antibodies against the n…
T. Jake Liang · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2022 · $1,991,797 — Therapy for hepatitis C virus (HCV) infection has advanced rapidly with the recent approval of several direct-acting antivirals. However, most of the DAAs in clinical use or clinical trials target the same stage of HCV replication cycle and are associated with rapid emergence of drug-resistant viral…
Donald Lo · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2022 · $775,431 — TDB scientists have extensive experience in developing novel therapeutic candidates as well as repurposing existing treatments for novel therapeutic purposes. Drug repurposing seeks to explore new uses for existing drugs and therapeutic candidates that already possess detailed pharmacology, formulat…
Heinrich Feldmann · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $456,404 — Orthohantavirues Introduction: Orthohantaviruses are largely rodent-borne viruses causing two clinical syndromes, hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardio-pulmonary syndrome (HCPS). Currently there are no approved vaccines or therapeutics available. The individual rodent ho…
PETER D. SUN · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $171,318 — To characterize the SARS-CoV-2 spike protein interaction with lectin receptors, we have expressed recombinant SARS-CoV-2 spike prefusion trimer using 293F freestyle expression system. Given the nanomolar high affinity of the spike protein binding to human ACE2, the entry receptor for SARS-CoV-2, an…
Andrea Marzi · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $46,470 — Summary 1. Intranasal single-dose vaccination with VSV-based COVID-19 vaccines protects hamsters from disease within 10 days We designed, cloned, and recovered two replication-competent VSV-based vaccines encoding the SARS-CoV-2 spike protein either alone (VSV-SARS2) or in combination with the EBOV …
Joshua Hoong Yu Tan · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $444,049 — The overarching goal of this project is to study the immune response to COVID-19 at the monoclonal level to increase our understanding of basic biology and develop new tools to combat disease. We have screened plasma from >100 acutely infected and convalescent COVID-19 individuals for neutralization…
Charles M Rice · ROCKEFELLER UNIVERSITY · 2022 · $1,454,501 — Project Summary – BSL3 Virology and Animal Models Core The COVID-19 pandemic has disrupted all aspects of society across the globe. The overarching theme of this P01 proposal is to study immune responses to infection with SARS-CoV-2 and their reactivity against other coronaviruses (CoVs) such that i…
Paul D. Bieniasz · ROCKEFELLER UNIVERSITY · 2022 · $1,454,501 — ABSTRACT-PROJECT 2 The SARS-CoV-2 pandemic has established beyond doubt that animal coronaviruses are a major potential threat to human health. Although vaccines and antibodies to prevent and treat SARS-CoV-2 infection have been developed at unprecedented speed, the recurrent emergence of coronavir…
alexander wlodawer · DIVISION OF BASIC SCIENCES - NCI · 2022 · $287,390 — Recently, angiotensin-converting enzyme 2 (ACE2) was shown to be a functional receptor for SARS-CoV-2, enabling the virus to enter host target cells. Using structure-based rational design, a chimeric ACE2 peptide was designed by us for use as a ligand for analytical quantitation of SA…
Christian Mayer · DIVISION OF BASIC SCIENCES - NCI · 2022 · $9,313 — This research was primarily carried out by the cooperating laboratories. One study characterized several monoclonal antibodies targeting distinct epitopes on the SARS-CoV2 spike protein. One especially potent antibody, XG014, was capable of neutralizing SARS-CoV2 as well as its varian…
Clare Michal Waterman · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2022 · $1,014,816 — Project: MARK2/Par1b regulates cytoskeleton polarization and directed cell migration through modulation of Myosin II contractility and focal adhesion organization. Personnel: Ana Pasapera Collaborators: Sarah Heissler, Masumi Eto Goal: We sought to test the hypothesis that MARK2 mediates polariza…